SCHEMBL2284265

SCHEMBL2284265

COC(=O)COc1ccc(/C=C/C(=O)c2c(O)cc(C)n(C)c2=O)cc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.48
PTGS2 P35354 1/20 0.43
MAPT P10636 6/20 0.41
KMT2A Q03164 5/20 0.41
KDM4E B2RXH2 4/20 0.41
MEN1 O00255 4/20 0.41
CYP3A4 P08684 2/20 0.41
HPGD P15428 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
ABCG2 Q9UNQ0 2/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
GAA P10253 3/20 0.39
LMNA P02545 3/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
SRC P12931 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2284270 1.00 APP (0.48) APPPTGS2MAPTKMT2AKDM4E
SCHEMBL2276772 0.84 ABCG2 (0.47) APPMAPTKDM4ECYP3A4HPGD
SCHEMBL2276769 0.84 ABCG2 (0.47) APPMAPTKDM4ECYP3A4HPGD
SCHEMBL2281909 0.83 APP (0.49) APPPTGS2MAPTKMT2AKDM4E
SCHEMBL2281911 0.83 APP (0.49) APPPTGS2MAPTKMT2AKDM4E
SCHEMBL12374830 0.80 ABCG2 (0.36) APPPTGS2MAPTKMT2AKDM4E
SCHEMBL2283107 0.78 CYSLTR2 (0.46) APPMAPTKDM4ECYP3A4HPGD
SCHEMBL2283102 0.78 CYSLTR2 (0.46) APPMAPTKDM4ECYP3A4HPGD
SCHEMBL2277293 0.77 APP (0.43) APPKMT2AKDM4EMEN1ABCG2
SCHEMBL2277289 0.77 APP (0.43) APPKMT2AKDM4EMEN1ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 APP 3864/4885PTGS2 376/4885MAPT 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.